Pharma IQ Members

104 results
of 11
January 3, 2018 by Chanice Henry
Chan
Pharma IQ takes a look at some of the trends forecasted to take hold this year: disruption for vendor landscapes, regulatory intervention and sophisticated analytics technologies gaining speed.
Tags:
September 26, 2017 by Dr Steven Bradshaw
Dr Steven Bradshaw
Pharma treads a fine line to the tipping point where there is insufficient time to recoup a drug’s costs, due to the number of years left that the patent can run.
Tags:
September 5, 2017 by Pharma IQ
Pharma IQ
As pharma spend continues to climb, so does public scrutiny on drug pricing. Once again, medicine manufacturers are spurred to strike a fair solution to balance raging its R&D appetites with affordable access to treatments for patients
Tags: pharma, medicine, drug, price, prices, spending, disease, treatment, cure, spend, R&D, manufacturers, Big pharma, biotech, small pharma
June 20, 2017 by Pharma IQ News
Pharma IQ News
The Reputation Institute has revealed the top 10 most reputable pharma companies as voted by the general public. In a surprising result, AstraZeneca and GSK both failed to make the top 10.
Tags:
April 18, 2017 by Ash Rishi
Ash Rishi
Patient education is an important factor in disease self-management, and when handled properly it has been found to have a significant, positive impact on improving patient outcomes.
Tags: Pharmaceutical, medicines, cure, treatment, drug, medicine, disease, condition, illness, sickness, patient, pharma, bio pharma, drug development, healthcare,
March 29, 2017 by Pharma IQ
Pharma IQ
As the term patient centricity continues to buzz in the pharma industry, data has emerged stating that US physicians have experienced an overwhelming amount of confusion from patients around direct to consumer (DTC) adverts.
Tags: medicine, medicines, healthcare, drugs, pharma, pharmaceuticals, cure, patient, patient centricity, adverts, advertising, physicians, confusion, DTC
February 14, 2017 by Social Monsters.org
default profile icon
After years of resistance, the health care and pharmaceutical industries are now accelerating full steam towards the cloud. In fact, the global health care cloud computing market, valued at $4.5 billion in 2016, will reach $9.5 billion by 2020. Here are the dominant benefits that are drawing these giants to the cloud.
Tags:
February 7, 2017 by Ash Rishi
Ash Rishi
When it comes to manoeuvrability and nimble response, large companies have more in common with ocean liners than speedboats. Policies are agreed, marketing strategies planned, and future developments or projects set in motion months or years in advance.
Tags:
104 results
of 11